Dragon fruit is a tropical superfood packed with vitamins, antioxidants, and fiber. Among many benefits, it can boost ...

You’ll likely be hearing more and more about NAD. But what's the difference between NAD+ and NADH, and should you take ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Many individuals are told that managing type 2 diabetes is simply a matter of controlling blood sugar. As long as glucos ...

SaveHealth explores what the research says about Ozempic's effects on insulin resistance and related conditions.

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

Opko Health Inc. and Entera Bio Ltd. have entered into a collaboration and license agreement to advance an oral dual agonist GLP-1/glucagon peptide as a once-daily tablet into the clinic for patients ...

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic ...

Glucagon-like peptide-1 (GLP-1) receptors, expressed in the central nervous system and peripheral tissues, have been found to affect gut motility. GLP-1 and its analog ROSE-010 have been shown to ...